AR070525A1 - Imidazolidin -2,4- dionas sustituidas con heterociclos , un proceso para su preparacion , medicamentos que las comprenden y su uso - Google Patents
Imidazolidin -2,4- dionas sustituidas con heterociclos , un proceso para su preparacion , medicamentos que las comprenden y su usoInfo
- Publication number
- AR070525A1 AR070525A1 ARP090100402A ARP090100402A AR070525A1 AR 070525 A1 AR070525 A1 AR 070525A1 AR P090100402 A ARP090100402 A AR P090100402A AR P090100402 A ARP090100402 A AR P090100402A AR 070525 A1 AR070525 A1 AR 070525A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- cycloalkyl
- aryl
- substituted
- heteroaryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Los compuestos son adecuados, por ejemplo como fármacos antiobesidad. Reivindicacion 1: Un compuesto de formula (1) en la que R, R' son cada uno, independientemente, H, (CH2)n-arilo, o alquilo C1-6, en que el radical alquilo C1-6 o arilo puede estar sustituido con halogeno, OR14, S(O)mR12 o NR13R15; o R y R' juntos forman un anillo que tiene de tres a ocho átomos de carbono, en que un átomo de carbono puede estar reemplazado por O, S(O)m, NR13 o NR15; m es 0, 1, 2; n es 0, 1, 2, 3, 4; p es 1, 2, 3, 4, 5; q es 1, 2, 3, 4; r es 2, 3, 4, 5, 6: v es 0, 1, 2, 3, 4; A, D, E, G, L son cada uno independientemente, C o N, en los que, cuando se definen como N el correspondiente sustituyente R1, R2, R3, R4, R5 está ausente, o R2-D=E-R3 o R4-G=L-R5 se definen como S u O y donde el anillo de cinco miembros o de seis miembros puede estar condensado con -(CH2)3- o -(CH2)4- o -CH=CH-CH=CH- para formar un sistema bicíclico; R1, R2, R3, R4, R5 son cada uno independientemente, H, F, CI, Br, I, CN, N3, NC, NO2, CF3, alquilo C1-8, cicloalquilo C3-8, (CH2)q-[cicloalquilo C3-8], (CH2)n-[cicloalquenilo C3-8], (CH2)n-[bicicloalquilo C7-12], (CH2)n-[tricicloalquilo C7-12], adamantan-1-ilo, adamantan-2-ilo, (CH2)n-arilo, (CH2)n-heteroarilo, OCF3, O-R11, NR13R15, NH-CN, S(O)m-R12, SO2-NH2, SO2-N=CHN(CH3)2, SO2-NH-[alquilo C1-8], SO2-NH-[cicloalquilo C3-8], SO2-NH-(CH2)n-arilo, SO2-NH-(CH2)n-heteroarilo, SO2-N[alquilo C1-8]2, SO2-R16, SF5, CO-O[alquilo C1-8], CO-O[cicloalquilo C3-8], CO-O-(CH2)n-arilo, CO-O-(CH2)n-heteroarilo, CONH2, CO-NH-CN, CO-NH-[alquilo C1-8], CO-N[alquilo C1-8]2, CO-NH-[cicloalquilo C3-8], CO-N[cicloalquilo C3-8]2, C(=NH)-O-[alquilo C1-6], C(=NH)-NH2, C(=NH)R16, C(=NR13)NR12R13, (CH2)n-C(=NSO2-R12)NH2, CO-R16, COOH, CO-alquilo C1-8, CO-cicloalquilo C3-8, CO-arilo, CO-heteroarilo, CH(OH)-arilo, CH(OH)-heteroarilo, CH[O-alquil C1-6]-arilo, CH[O-alquil C1-6]-heteroarilo, CHF-arilo, CHF-heteroarilo, CF2-arilo, CF2-heteroarilo, CHO, CH2-OH, CH2-CN, CH2-OR12, CH2-O-(CH2)n-CO-O[alquilo C1-8], CH2-O-(CH2)n-CO-NH2, CH2-O-(CH2)q-COOH, en los que los radicales alquilo, cicloalquilo, cicloalquenilo, bicicloalquilo, bicicloalquenilo y tricicloalquilo pueden estar sustituidos con átomos de fluor y en donde los radicales arilo o heteroarilo pueden estar sustituidos con halogeno, CN, alquilo C1-6, cicloalquilo C3-6, O-alquilo C1-6, OCF3, OH, (CH2)n-arilo, O-(CH2)n-arilo, S(O)m-alquilo C1-6, SO2-NH2, SH, NR12R13, NH-CO-[alquilo C1-6], NH-CO-(CH2)n-arilo, (CH2)n-COOH, (CH2)n-CONH2, (CH2)n-CO-O-alquilo C1-6, o (CH2)n-CO-alquilo C1-6 y en los que los radicales alquilo pueden estar sustituidos con átomos de fluor; R6, R7, R8, R9, R10 son cada uno independientemente, R11, T-heterociclo bicíclico-U-R40, T-aril-U-R40 o T-heteroaril-U-R40, en los que el heterociclo bicíclico o el radical arilo o heteroarilo puede estar condensado a un anillo de carbono aromático o no aromático de 5 o 6 miembros, en el que uno o más grupos CH o CH2 pueden reemplazarse por átomos de oxígeno y en el que el anillo de carbono aromático o no aromático de 5 o 6 miembros puede estar sustituido con F, =O o alquilo C1-6 y en el que el heterociclo bicíclico puede contener de 9 a 12 miembros de anillo y hasta cinco grupos CH o CH2 pueden estar reemplazados independientemente por N, NR20, O, S(O)m o C=O y en los que el radical arilo o heteroarilo o el heterociclo bicíclico puede no estar sustituido o puede estar mono o polisustituido con R11, F, CI, Br, I, CN, N3, NC, NO2, CF3, (CH2)n-O-R11, O-R13, OCF3, (CH2)n-NH-R11, (CH2)n-N[(CH2)q-CO-O-alquilo C1-6]2, (CH2)n-N[(CH2)q-COOH]2, (CH2)n-N[(CH2)q-CONH2]2, (CH2)n-NH-R13, (CH2)n-N(R13)2, (CH2)n-NH-SO2-R16, (CH2)n-NH-(CH2)n-SO2-R12, (CH2)n-NR12-CO-R16, (CH2)n-NR12-CO-NR12R13, (CH2)n-NR12-CO-N(R12)2, (CH2)n-NH-C(=NH)-NH2, (CH2)n-NH-C(=NH)-R16, (CH2)n-NH-C(=NH)-NHR12, (CH2)n-NH-(CH2)n-CO-NH-[alquilo C1-8], (CH2)n-NH-(CH2)n-CO-N[alquilo C1-8]2, (CH2)n-NH-(CH2)n-CO-NH-[cicloalquilo C3-8], (CH2)n-NH-(CH2)n-CO-N[cicloalquilo C3-8]2, (CH2)n-NH-C(CH3)2-CO-O-alquilo C1-8, (CH2)n-NH-C(CH3)2-CO-O-cicloalquilo C3-8, (CH2)n-NH-C(CH3)2-CO-O-(CH2)n-arilo, (CH2)n-NH-C(CH3)2-CO-O-(CH2)n-heteroarilo, (CH2)n-NH-C(CH3)2-CO-NH2, (CH2)n-NH-C(CH3)2-CO-NH-[alquilo C1-8], (CH2)n-NH-C(CH3)2-CO-N[alquilo C1-8]2, (CH2)n-NH-(CH3)2-CO-NH-[cicloalquilo C3-8], (CH2)n-NH-C(CH3)2-CO-N[cicloalquilo C3-8]2, (CH2)n-NH-C(CH3)2-COOH, (CH2)n-S(O)m-R18, S(O)mR12, SO2R16, SO2-N=CH-N(CH3)2, el resto formula (2), SO2-NH-COR12, SO2-NHR12, SO2-N[alquilo C1-8]2, SF5, COOH, CO-NH2, (CH2)q-CN, (CH2)n-CO-NH-CN, (CH2)n-CO-NH-piperidin-1-ilo, (CH2)n-CO-NH-SO2-NHR12, (CH2)N-CO-NH-SO2-R18, (CH2)n-CHO, (CH2)n-C(=NH)-NH2, (CH2)n-C(=NH)-NHOH, (CH2)n-C(=NH)-[NH-O-alquilo C1-6], (CH2)n-C(=NH)(R16), (CH2)n-C(=NR13)-NHR12, (CH2)n-C(=NR12)-NR12R13, (CH2)n-C(=NSO2-R12)-NH2, o (CH2)n-C(=NH)O[alquilo C1-6], en los que los radicales alquilo y cicloalquilo pueden estar sustituidos con átomos de fluor y en los que los radicales arilo o heteroarilo pueden estar sustituidos con halogeno, CN, CF3, alquilo C1-6, cicloalquilo C3-6, O-alquilo C1-6, OCF3, OH, SH, S(O)m-alquilo C1-6, SO2-NH2, NR12R13, NH-CO-[alquilo C1-6], NH-CO-(CH2)n-arilo, (CH2)n-COOH, (CH2)n-CONH2, (CH2)n-COO-alquilo C1-6, (CH2)n-CO-alquilo C1-6, y en los que los radicales alquilo pueden estar sustituidos con átomos de fluor, F, CI, Br, I, CN, N3, NC, NO2, CF3, (CH2)n-O-R11, (CH2)n-O-(CH2)n-CO-O-(CH2)n-NH2, O-R13, OCF3, (CH2)n-NH-R11, (CH2)n-NH-R13, (CH2)n-NH-SO2-R16, (CH2)n-NH-(CH2)n-SO2-R12, (CH2)n-NR12-CO-N(R12)2, (CH2)n-NH-C(=NH)-R16, (CH2)n-NH-C(=NH)-NHR12, (CH2)n-NR12-C(=NR13)-NHR12, (CH2)n-NR12-C(=NR12)-NR12R13, (CH2)n-NH-(CH2)n-CO-NH-[alquilo C1-8], (CH2)n-NH-(CH2)n-CO-N[alquilo C1-8]2, (CH2)n-NH-(CH2)n-CO-NH-[cicloalquilo C3-8], (CH2)n-NH-(CH2)n-CO-N[cicloalquilo C3-8]2, S(O)mR12, SO2R16, SO2-N=CH-N(CH3)2, el resto de formula (2), SO2-NHR12, SO2-N[alquilo C1-8]2, SF5, COOH, CO-NH2, (CH2)q-CN, (CH2)n-CHO, (CH2)n-C(=NH)-NHOH, (CH2)n-C(=NH)(R16), (CH2)n-C(=NR13)-NHR12, (CH2)n-C(=NR12)-NR12R13, (CH2)n-C(=NH)O[alquilo C1-6], en los que los radicales alquilo y cicloalquilo pueden estar sustituidos con átomos de fluor y donde los radicales arilo o heteroarilo pueden estar sustituidos con halogeno, CN, alquilo C1-6, cicloalquilo C3-6, O-alquilo C1-6, OCF3, SH, S(O)m-alquilo C1-6, SO2-NH2, NR12R13, NH-CO-alquilo C1-6, NH-CO-(CH2)n-arilo, (CH2)n-COOH, (CH2)n-CONH2, (CH2)n-CO-[O-alquilo C1-6], (CH2)n-CO-alquilo C1-6, y en los que los radicales alquilo pueden estar sustituidos con átomos de fluor; en los que al menos uno de los radicales R6, R7, R8, R9 y R10 siempre se define como T-heterociclo bicíclico-U-R40, T-aril-U-R40 o T-heteroaril-U-R40; y en los que una de las cuatro parejas de radicales de R6 y R7, o R7 y R8, o R8 y R9, o R9 y R10 pueden formar juntas, en cada caso, los grupos -CH2-CH2-CH2- o -CH2-CH2-CH2-CH2- en los que hasta dos grupos -CH2- se pueden reemplazar por -O- y en donde los grupos -CH2-CH2-CH2- o -CH2-CH2-CH2-CH2- pueden estar sustituidos con F, alquilo C1-8 o =O; T es NR17, O, S(O)m, C(Q1Q2), CO, NR23-CO-NR24, NR23-SO2-NR24, SO2-NR23-SO2, CO-NR23-CO, NR23-C(=NR13)-NR24, NR23-C(=NR22)-NR24, CO-NR23-CR22R23, NR23-SO2-CR22R24, CR22R24-CO-NR23, CR22R23-NR23-SO2, SO2-CR22R23-NR23, SO2-NR23-CR22R23, NR23-CR22R23-SO2, CR23R24-CR23R24-CR23R24 ; U es un enlace, (CH2)n-C(Q1Q2), (CH2)n-O, O-alquilo C1-6, (CH2)n-S(O)m, S(O)m-alquilo C1-6, (CH2)n-NR23, NR23-alquilo C1-6; R40 es un heterociclo, un heterociclo bicíclico o un heterociclo tricíclico, en los que el radical heterocíclico, el radical heterocíclico bicíclico, el radical heterocíclico tricíclico puede estar sustituido con halogeno, CN, CF3, alquilo C1-6, cicloalquilo C3-6, O-alquilo C1-6, OCF3, OH, SH, S(O)m-alquilo C1-6, S(O)m-cicloalquilo C3-6, SO2-NH2, SO3H, S(O)m-R18, NR12R13, NH-CO-[alquilo C1-6], NH-CO-(CH2)n-arilo, (CH2)n-COOH, (CH2)n-CONH2, (CH2)n-COO-alquilo C1-6, (CH2)n-CO-alquilo C1-6, (CH2)n-C(=NR13)NHR12, (CH2)n-C(=NSO2-R12)NH2 o (CH2)n-NR12-C(=NR12)-NR12R13, en la que R40 es un azucar cíclico no sustituido o sustituido, o un ácido de azucar cíclico no sustituido o sustituido; Q1 y Q2 son cada uno independientemente H, alquilo C1-6, F, OH, OR12, O-CO-OR12, O-CO-R12, NH2, NHR12, NHR13, N(R12)2, NHCOR12, o Q1 y Q2 junto con el átomo de carbono al cual están unidos, forman un carbociclo que tiene de 3 a 8 átomos de carbono; R11 es H, alquilo C1-8, alquenilo C2-10, alquinilo C2-10, cicloalquilo C3-8, (CH2)q-[cicloalquilo C3-8], (CH2)n-arilo , (CH2)n-CO-[O-alquilo C1-8], (CH2)n-CO-[O-cicloalquilo C3-8], (CH2)n-CO-[alquilo C1-8], (CH2)n-CO-[cicloalquilo C3-8], (CH2)n-CO-arilo, (CH2)n-CO-heteroarilo, (CH2)q-CO-NH2, (CH2)q-COOH, (CH2)n-P(O)(OH)[O-alquilo C1-6], (CH2)n-P(O)[O-alquilo C1-6]2, (CH2)n-P(O)(OH)(O-CH2-arilo), (CH2)n-P(O)(O-CH2-arilo)2, (CH2)n-P(O)(OH)2, (CH2)n-SO3H, (CH2)n-SO2-NH2, (CH2)n-CO-NH-[alquilo C1-8], (CH2)n-CO-N[alquilo C1-8]2, (CH2)n-CO-NH-[cicloalquilo C3-8], alquenil C2-10-CO-O-[alquilo C1-6], alquenil C2-10-CO-NH2, alquenil C2-10-COOH, alquinil C2-10-COO-[alquilo C1-8], alquinil C2-10-CO-NH2, alquinil C2-10-COOH, (CH2)n-CR21-[CO-O-alquilo C1-6]2, (CH2)n-CR21-(CONH2)2, (CH2)n-CR21(COOH)2, (CH2)n-CR21R22CO-O[alquilo C1-6], (CH2)n-CR21R22-CONH2, (CH2)n-CR21R22-CO-NH-[alquilo C1-8], (CH2)n-CR21R22-CO-N[alquilo C1-8]2, (CH2)n-CR21R22COOH, (CH2)n-CO-R16, (CH2)n-CO-NH-C(CH3)2-COO[alquilo C1-8], (CH2)n-CO-NH-C(CH3)2-CONH2, (CH2)n-CO-NH-C(CH3)2-COOH, en los que los radicales alquilo, alquenilo, alquinilo y cicloalquilo, pueden estar sustituidos con átomos de fluor y en donde el radical arilo o heteroarilo puede estar sustituido con halogeno, CN, alquilo C1-6, cicloalquilo C3-6, O-alquilo C1-6, S(O)m-alquilo C1-6, SO2-NH2, COOH, CONH2, CO-O-alquilo C1-6, CO-alquilo C1-6 y en los que los radicales alquilo pueden estar sustituidos con átomos de fluor; R12 es H, alquilo C1-8, cicloalquilo C1-8, (CH2)n-arilo, (CH2)n-heteroarilo, en los que los radicales alquilo o cicloalquilo pueden estar sustituidos con átomos de fluor, y en los que el radical a
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08290134 | 2008-02-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR070525A1 true AR070525A1 (es) | 2010-04-14 |
Family
ID=39507676
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP090100402A AR070525A1 (es) | 2008-02-07 | 2009-02-05 | Imidazolidin -2,4- dionas sustituidas con heterociclos , un proceso para su preparacion , medicamentos que las comprenden y su uso |
Country Status (7)
Country | Link |
---|---|
US (1) | US20110046105A1 (es) |
EP (1) | EP2242746A1 (es) |
AR (1) | AR070525A1 (es) |
CL (1) | CL2009000258A1 (es) |
TW (1) | TW200946507A (es) |
UY (1) | UY31641A1 (es) |
WO (1) | WO2009098000A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3159331A1 (en) | 2010-05-05 | 2017-04-26 | Infinity Pharmaceuticals, Inc. | Tetrazolones as inhibitors of fatty acid synthase |
JP2013230986A (ja) * | 2010-08-25 | 2013-11-14 | Kyorin Pharmaceutical Co Ltd | 新規ヒダントイン誘導体及びそれらを有効成分とする医薬 |
US20130197043A1 (en) | 2010-08-31 | 2013-08-01 | Snu R&Db Foundation | Use of the fetal reprogramming of a ppar agonist |
WO2017059135A1 (en) * | 2015-10-02 | 2017-04-06 | Abide Therapeutics, Inc. | Lp-pla2 inhibitors |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5411981A (en) * | 1991-01-09 | 1995-05-02 | Roussel Uclaf | Phenylimidazolidines having antiandrogenic activity |
BRPI0715160A2 (pt) * | 2006-08-08 | 2013-06-11 | Sanofi Aventis | imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso |
-
2009
- 2009-01-30 EP EP09708060A patent/EP2242746A1/de not_active Withdrawn
- 2009-01-30 WO PCT/EP2009/000593 patent/WO2009098000A1/de active Application Filing
- 2009-02-05 TW TW098103589A patent/TW200946507A/zh unknown
- 2009-02-05 AR ARP090100402A patent/AR070525A1/es unknown
- 2009-02-05 CL CL2009000258A patent/CL2009000258A1/es unknown
- 2009-02-06 UY UY031641A patent/UY31641A1/es not_active Application Discontinuation
-
2010
- 2010-08-06 US US12/852,233 patent/US20110046105A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
UY31641A1 (es) | 2009-08-31 |
US20110046105A1 (en) | 2011-02-24 |
WO2009098000A1 (de) | 2009-08-13 |
EP2242746A1 (de) | 2010-10-27 |
TW200946507A (en) | 2009-11-16 |
CL2009000258A1 (es) | 2009-06-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR070579A1 (es) | Imidazolina -2,4- dionas sustituidas procesos para su preparacion medicamentos que comprenden estos compuestos y uso de los mismos | |
AR062221A1 (es) | Imidazolidina-2,4- dionas sustituidas con arilaminoarilalquilo, medicamentos que comprenden estos compuestos y su uso | |
BRPI0617880B8 (pt) | composto derivado de piridina substituído por heterociclo, composição farmacêutica, medicamento e agente antifúngico que compreende o dito composto e uso do mesmo para prevenir e/ou tratar infecção fúngica | |
AR124369A1 (es) | Inhibidores de prmt5 novedosos | |
HRP20160374T1 (hr) | Farmaceutski spojevi | |
ATE463483T1 (de) | 6-substituierte isochinolinderivate als rock-1- inhibitoren | |
CA2628131A1 (en) | Hydroxy and alkoxy substituted 1h-imidazoquinolines and methods | |
AR058388A1 (es) | DERIVADOS DE COMPUESTOS AROMATICOS SUSTITUIDOS uTILES PARA TRASTORNOS RESPIRATORIOS , COMPOSICIONES FARMACÉUTICAS Y PROCESOS PARA SU PREPARACIoN | |
AR060658A1 (es) | Derivados de diceto-piperazina y piperidina como agentes antivirales | |
RU2014141579A (ru) | Гетероциклические соединения в качестве ингибиторов бета-лактамаз | |
AR064389A1 (es) | Derivados heterociclicos de nicotinamida utiles en el tratamiento de afecciones y enfermedades alergicas y respiratorias, y composiciones farmaceuticas que los contienen. | |
EA200600258A1 (ru) | Триазолопиримидиновые производные в качестве ингибиторов киназы-3 гликогенсинтазы | |
AR076486A1 (es) | Inhibidores de fosfoinositida 3 kinasa y composiciones farmaceuticas que los contienen. | |
RU2430923C2 (ru) | Тиазолилдигидрохиназолины | |
BRPI0707491B8 (pt) | compostos úteis como agentes moduladores de receptores de mineralocorticóides, os referidos agentes compreendendo os mesmos e composições farmacêuticas | |
DK2091948T3 (da) | Nye inhibitorer af glutaminylcyclase | |
NO20082976L (no) | Svovelholdige cykliske ureaderivater, fremstilling derav og farmasoytisk anvendelse derav som kinaseinhibitorer | |
ES2605152T3 (es) | Derivados de pirazolquinolinona, su preparación y su uso terapéutico | |
AR069494A1 (es) | Derivados de acidos fosfonicos | |
AR083872A1 (es) | Derivados de acido carbamoil-cicloalquil-acetico sustituidos como inhibidores de nep | |
AR070525A1 (es) | Imidazolidin -2,4- dionas sustituidas con heterociclos , un proceso para su preparacion , medicamentos que las comprenden y su uso | |
EA201190119A1 (ru) | ПРОИЗВОДНЫЕ ТРИАЗОЛОПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ МАР-КИНАЗЫ p38 | |
BR112012011310A2 (pt) | compostos derivados de 8-azabiciclo[3.2.1]octano-8-carboxamida, seu medicamento, seu agente terapêutico e seu uso | |
MX2022000854A (es) | Derivados de 2-morfolinopiridina sustituidos como inhibidores de la cinasa atr. | |
MX2011012057A (es) | Derivados de ciclopenta [c] pirrolilalquilcarbamatos de heterociclos de 5 miembros, su preparación y su uso en terapéutica. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |